UniQure (QURE) shares continue rally, surging 109% in recent Tuesday trading after Wells Fargo upgraded the company's stock to overweight from equalweight, with a $35 price target.
The upgrade follows the company's announcement that it reached an agreement with the US Food and Drug Administration on elements of an Accelerated Approval pathway for its drug AMT-130, a potential treatment for Huntington's disease.
Trading volume stood at over 53.6 million shares against a daily average of about 780,000.
Price: 15.22, Change: +7.93, Percent Change: +108.69